Physician profile
Deepa Abhilash
NPI 1831718972
$4,565.58
in general payments reported to CMS, 2019-2025
23 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.24 · 2022: $872 · 2023: $1,200 · 2024: $1,204 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,675.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $702.40 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $556.43 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $450.15 | 2022-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $421.19 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $371.68 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $356.82 | 2022-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $315.84 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $233.35 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $206.25 | 2022-2024 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.23 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $127.13 | 2023-2024 | Trintellix |
| Genzyme Corporation | $125.00 | 2022 | |
| Indivior INC. | $124.56 | 2022-2025 | Perseris, Sublocade |
| Vanda Pharmaceuticals INC. | $111.61 | 2024-2025 | Fanapt, Hetlioz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.41 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $77.48 | 2024 | |
| Idorsia Pharmaceuticals US INC | $34.18 | 2023-2024 | Quviviq |
| Tris Pharma INC | $32.24 | 2023-2024 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $20.11 | 2022 | |
| Gilead Sciences, INC. | $19.98 | 2023 | |
| Lilly USA, LLC | $18.24 | 2021 | |
| Janssen Scientific Affairs, LLC | $15.53 | 2024 | Invega Sustenna |
| Tempus Ai, INC | $14.77 | 2024 | Tempus Pixel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Abhilash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.